These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15967099)

  • 1. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.
    Robinson SP; Kalber TL; Howe FA; McIntyre DJ; Griffiths JR; Blakey DC; Whittaker L; Ryan AJ; Waterton JC
    Neoplasia; 2005 May; 7(5):466-74. PubMed ID: 15967099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.
    Robinson SP; Howe FA; Griffiths JR; Ryan AJ; Waterton JC
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):872-9. PubMed ID: 17889267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
    Robinson SP; McIntyre DJ; Checkley D; Tessier JJ; Howe FA; Griffiths JR; Ashton SE; Ryan AJ; Blakey DC; Waterton JC
    Br J Cancer; 2003 May; 88(10):1592-7. PubMed ID: 12771928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
    McPhail LD; Griffiths JR; Robinson SP
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
    Evelhoch JL; LoRusso PM; He Z; DelProposto Z; Polin L; Corbett TH; Langmuir P; Wheeler C; Stone A; Leadbetter J; Ryan AJ; Blakey DC; Waterton JC
    Clin Cancer Res; 2004 Jun; 10(11):3650-7. PubMed ID: 15173071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.
    McIntyre DJ; Robinson SP; Howe FA; Griffiths JR; Ryan AJ; Blakey DC; Peers IS; Waterton JC
    Neoplasia; 2004; 6(2):150-7. PubMed ID: 15140404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors.
    Rodrigues LM; Howe FA; Griffiths JR; Robinson SP
    J Magn Reson Imaging; 2004 Apr; 19(4):482-8. PubMed ID: 15065173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
    Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
    Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.
    Madhu B; Waterton JC; Griffiths JR; Ryan AJ; Robinson SP
    Neoplasia; 2006 Jul; 8(7):560-7. PubMed ID: 16867218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
    Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
    Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells.
    Masunaga S; Nagasawa H; Nagata K; Suzuki M; Uto Y; Hori H; Kinashi Y; Ono K
    J Cancer Res Clin Oncol; 2007 Jan; 133(1):47-55. PubMed ID: 16924543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
    Kleespies A; Köhl G; Friedrich M; Ryan AJ; Barge A; Jauch KW; Bruns CJ
    Neoplasia; 2005 Oct; 7(10):957-66. PubMed ID: 16242078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats.
    Chen F; De Keyzer F; Feng YB; Cona MM; Yu J; Marchal G; Oyen R; Ni YC
    World J Gastroenterol; 2013 Dec; 19(47):9092-103. PubMed ID: 24379636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
    LoRusso PM; Gadgeel SM; Wozniak A; Barge AJ; Jones HK; DelProposto ZS; DeLuca PA; Evelhoch JL; Boerner SA; Wheeler C
    Invest New Drugs; 2008 Apr; 26(2):159-67. PubMed ID: 18219445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
    Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
    Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126.
    Vogel-Claussen J; Gimi B; Artemov D; Bhujwalla ZM
    Cancer Biol Ther; 2007 Sep; 6(9):1469-75. PubMed ID: 17881899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
    Siemann DW; Rojiani AM
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):846-53. PubMed ID: 15936569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
    Siemann DW; Rojiani AM
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1512-7. PubMed ID: 12459379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.